Patrick Donnelly
Stock Analyst at Citigroup
(3.49)
# 869
Out of 5,182 analysts
349
Total ratings
47.92%
Success rate
4.93%
Average return
Main Sectors:
Stocks Rated by Patrick Donnelly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $18 → $24 | $22.28 | +7.72% | 14 | Apr 7, 2026 | |
| BIO Bio-Rad Laboratories | Downgrades: Neutral | $375 → $300 | $287.29 | +4.42% | 18 | Apr 7, 2026 | |
| BIO.B Bio-Rad Laboratories | Downgrades: Neutral | $375 → $300 | $291.46 | +2.93% | 18 | Apr 7, 2026 | |
| MDLN Medline | Reinstates: Buy | $60 | $45.23 | +32.66% | 3 | Mar 11, 2026 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $200 → $120 | $103.21 | +16.27% | 11 | Mar 11, 2026 | |
| STVN Stevanato Group | Maintains: Buy | $32 → $26 | $16.18 | +60.69% | 5 | Mar 5, 2026 | |
| SHC Sotera Health Company | Maintains: Buy | $21 → $23 | $15.81 | +45.48% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Buy | $135 → $150 | $88.50 | +69.49% | 12 | Feb 20, 2026 | |
| BRKR Bruker | Maintains: Neutral | $53 → $40 | $36.53 | +9.50% | 19 | Feb 13, 2026 | |
| QDEL QuidelOrtho | Maintains: Neutral | $23 → $30 | $12.29 | +144.10% | 7 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $7.97 | +38.02% | 9 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $215 | $196.63 | +9.34% | 12 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $55 | $38.09 | +44.39% | 15 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $230 → $200 | $163.84 | +22.07% | 14 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $80 | $55.11 | +45.16% | 13 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $685 | $468.04 | +46.36% | 22 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $265 | $171.23 | +54.76% | 22 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $300 | $204.39 | +46.78% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $21 | $10.60 | +98.11% | 5 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $185 | $115.62 | +60.01% | 27 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,600 → $1,700 | $1,274.70 | +33.36% | 15 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $42 | $19.93 | +110.74% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $85 → $80 | $128.52 | -37.75% | 17 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $265 | $180.62 | +46.72% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $145 | $86.80 | +67.05% | 1 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $265 → $300 | $299.79 | +0.07% | 24 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $3.01 | +199.00% | 6 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.75 → $2.75 | $2.00 | +37.50% | 4 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $250 → $260 | $263.43 | -1.30% | 11 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $5.96 | +0.67% | 4 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $28 → $32 | $4.83 | +562.53% | 2 | Nov 30, 2018 |
10x Genomics
Apr 7, 2026
Maintains: Neutral
Price Target: $18 → $24
Current: $22.28
Upside: +7.72%
Bio-Rad Laboratories
Apr 7, 2026
Downgrades: Neutral
Price Target: $375 → $300
Current: $287.29
Upside: +4.42%
Bio-Rad Laboratories
Apr 7, 2026
Downgrades: Neutral
Price Target: $375 → $300
Current: $291.46
Upside: +2.93%
Medline
Mar 11, 2026
Reinstates: Buy
Price Target: $60
Current: $45.23
Upside: +32.66%
ICON Public Limited Company
Mar 11, 2026
Maintains: Neutral
Price Target: $200 → $120
Current: $103.21
Upside: +16.27%
Stevanato Group
Mar 5, 2026
Maintains: Buy
Price Target: $32 → $26
Current: $16.18
Upside: +60.69%
Sotera Health Company
Feb 24, 2026
Maintains: Buy
Price Target: $21 → $23
Current: $15.81
Upside: +45.48%
Guardant Health
Feb 20, 2026
Maintains: Buy
Price Target: $135 → $150
Current: $88.50
Upside: +69.49%
Bruker
Feb 13, 2026
Maintains: Neutral
Price Target: $53 → $40
Current: $36.53
Upside: +9.50%
QuidelOrtho
Feb 12, 2026
Maintains: Neutral
Price Target: $23 → $30
Current: $12.29
Upside: +144.10%
Feb 12, 2026
Maintains: Neutral
Price Target: $13 → $11
Current: $7.97
Upside: +38.02%
Feb 10, 2026
Maintains: Neutral
Price Target: $190 → $215
Current: $196.63
Upside: +9.34%
Feb 6, 2026
Maintains: Neutral
Price Target: $55 → $55
Current: $38.09
Upside: +44.39%
Feb 6, 2026
Maintains: Neutral
Price Target: $230 → $200
Current: $163.84
Upside: +22.07%
Feb 5, 2026
Maintains: Buy
Price Target: $70 → $80
Current: $55.11
Upside: +45.16%
Jan 30, 2026
Maintains: Buy
Price Target: $660 → $685
Current: $468.04
Upside: +46.36%
Jan 16, 2026
Maintains: Buy
Price Target: $200 → $265
Current: $171.23
Upside: +54.76%
Jan 7, 2026
Initiates: Buy
Price Target: $300
Current: $204.39
Upside: +46.78%
Dec 11, 2025
Upgrades: Buy
Price Target: $12 → $21
Current: $10.60
Upside: +98.11%
Nov 25, 2025
Maintains: Buy
Price Target: $165 → $185
Current: $115.62
Upside: +60.01%
Nov 10, 2025
Maintains: Buy
Price Target: $1,600 → $1,700
Current: $1,274.70
Upside: +33.36%
Aug 13, 2025
Maintains: Buy
Price Target: $34 → $42
Current: $19.93
Upside: +110.74%
Jul 9, 2025
Downgrades: Sell
Price Target: $85 → $80
Current: $128.52
Upside: -37.75%
Jan 30, 2025
Maintains: Buy
Price Target: $285 → $265
Current: $180.62
Upside: +46.72%
Jul 30, 2024
Maintains: Buy
Price Target: $135 → $145
Current: $86.80
Upside: +67.05%
Dec 11, 2023
Maintains: Neutral
Price Target: $265 → $300
Current: $299.79
Upside: +0.07%
Dec 11, 2023
Maintains: Buy
Price Target: $7 → $9
Current: $3.01
Upside: +199.00%
Aug 10, 2023
Maintains: Neutral
Price Target: $3.75 → $2.75
Current: $2.00
Upside: +37.50%
Feb 17, 2023
Maintains: Neutral
Price Target: $250 → $260
Current: $263.43
Upside: -1.30%
Nov 3, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $5.96
Upside: +0.67%
Nov 30, 2018
Upgrades: Neutral
Price Target: $28 → $32
Current: $4.83
Upside: +562.53%